124 related articles for article (PubMed ID: 23009609)
21. Zoledronic acid prevents cancer treatment-induced bone loss.
Oncology (Williston Park); 2005 Mar; 19(3):390. PubMed ID: 15828553
[No Abstract] [Full Text] [Related]
22. Inappropriate ATAC on tamoxifen.
Ucci G
Lancet Oncol; 2008 Apr; 9(4):314-5. PubMed ID: 18374286
[No Abstract] [Full Text] [Related]
23. [Breast carcinoma: new, much promising trends. The cancer anxiety of women -- will be taken better care soon?].
Aumiller J
MMW Fortschr Med; 2005 Mar; 147(10):4-6. PubMed ID: 15803773
[No Abstract] [Full Text] [Related]
24. Aromatase inhibitors for the treatment and prevention of breast cancer.
Kalidas M; Brown P
Clin Breast Cancer; 2005 Apr; 6(1):27-37. PubMed ID: 15899070
[TBL] [Abstract][Full Text] [Related]
25. Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study.
Aihara T; Takatsuka Y; Ohsumi S; Aogi K; Hozumi Y; Imoto S; Mukai H; Iwata H; Watanabe T; Shimizu C; Nakagami K; Tamura M; Ito T; Masuda N; Ogino N; Hisamatsu K; Mitsuyama S; Abe H; Tanaka S; Yamaguchi T; Ohashi Y
Breast Cancer Res Treat; 2010 Jun; 121(2):379-87. PubMed ID: 20390343
[TBL] [Abstract][Full Text] [Related]
26. The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment.
Duffy S; Jackson TL; Lansdown M; Philips K; Wells M; Pollard S; Clack G; Coibion M; Bianco AR
Hum Reprod; 2006 Feb; 21(2):545-53. PubMed ID: 16210385
[TBL] [Abstract][Full Text] [Related]
27. Breast cancer (metastatic).
Stebbing J; Crane J; Gaya A
Clin Evid; 2006 Jun; (15):2331-59. PubMed ID: 16973089
[No Abstract] [Full Text] [Related]
28. Update on adjuvant hormonal treatment of early breast cancer.
Lao Romera J; Puertolas Hernández TJ; Peláez Fernández I; Sampedro Gimeno T; Fernández Martínez R; Fernández Pérez I; Iranzo González Cruz V; Illarramendi Mañas JJ; Garcerá Juan S; Ciruelos Gil EM
Adv Ther; 2011 Sep; 28 Suppl 6():1-18. PubMed ID: 21922392
[TBL] [Abstract][Full Text] [Related]
29. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
Gradishar WJ
Oncology; 2005; 69(1):1-9. PubMed ID: 16088229
[TBL] [Abstract][Full Text] [Related]
30. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.
Boccardo F; Rubagotti A; Puntoni M; Guglielmini P; Amoroso D; Fini A; Paladini G; Mesiti M; Romeo D; Rinaldini M; Scali S; Porpiglia M; Benedetto C; Restuccia N; Buzzi F; Franchi R; Massidda B; Distante V; Amadori D; Sismondi P
J Clin Oncol; 2005 Aug; 23(22):5138-47. PubMed ID: 16009955
[TBL] [Abstract][Full Text] [Related]
31. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
[TBL] [Abstract][Full Text] [Related]
32. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study.
Jenkins V; Shilling V; Fallowfield L; Howell A; Hutton S
Psychooncology; 2004 Jan; 13(1):61-6. PubMed ID: 14745746
[TBL] [Abstract][Full Text] [Related]
33. [Therapy concept: herceptin in combination with arimidex].
von Minckwitz G
Onkologie; 2002 Dec; 25 Suppl 5():22 ; discussion 22-4. PubMed ID: 23573617
[No Abstract] [Full Text] [Related]
34. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
35. Extended adjuvant therapy with letrozole: reducing the risk of recurrence.
Dixon JM
Expert Rev Anticancer Ther; 2006 Jun; 6(6):849-59. PubMed ID: 16761928
[TBL] [Abstract][Full Text] [Related]
36. Cutaneous adverse effects of hormonal adjuvant therapy for breast cancer: a case of localised urticarial vasculitis following anastrozole therapy and a review of the literature.
Bock VL; Friedlander M; Waring D; Kossard S; Wood GK
Australas J Dermatol; 2014 Nov; 55(4):282-5. PubMed ID: 24575835
[TBL] [Abstract][Full Text] [Related]
37. Breast cancer prevention.
Thornton H
Br J Gen Pract; 2003 Feb; 53(487):150. PubMed ID: 12817365
[No Abstract] [Full Text] [Related]
38. Update: a 62-year-old woman with a new diagnosis of breast cancer.
Farag N; Burns R; Come SE
JAMA; 2008 Mar; 299(9):1055-6. PubMed ID: 18319415
[No Abstract] [Full Text] [Related]
39. Lobular carcinoma of the breast metastasizing to leiomyoma in a patient under letrozole treatment.
Işçi H; Güdücü N; Basgul AY; Aydinli K; Calay Z; Dünder I
Eur J Gynaecol Oncol; 2011; 32(5):560-2. PubMed ID: 22053676
[TBL] [Abstract][Full Text] [Related]
40. Alopecia in a premenopausal breast cancer woman treated with letrozole and triptorelin.
Carlini P; Di Cosimo S; Ferretti G; Papaldo P; Fabi A; Ruggeri EM; Milella M; Cognetti F
Ann Oncol; 2003 Nov; 14(11):1689-90. PubMed ID: 14581280
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]